Abstract:BACKGROUND:PRDM (PRDI-BF1 and RIZ domain containing) proteins are zinc finger proteins involved in multiple cellular regulations by acting as epigenetic modifiers. We studied a recently identified PRDM member PRDM5 for its epigenetic abnormality and tumor suppressive functions in multiple tumorigeneses.METHODOLOGY/PRINCIPAL FINDINGS:Semi-quantitative RT-PCR showed that PRDM5 was broadly expressed in human normal tissues, but frequently silenced or downregulated in multiple carcinoma cell lines due to promoter CpG methylation, including 80% (4/5) nasopharyngeal, 44% (8/18) esophageal, 76% (13/17) gastric, 50% (2/4) cervical, and 25% (3/12) hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell lines. PRDM5 expression could be restored by 5-aza-2'-deoxycytidine demethylation treatment in silenced cell lines. PRDM5 methylation was frequently detected by methylation-specific PCR (MSP) in multiple primary tumors, including 93% (43/46) nasopharyngeal, 58% (25/43) esophageal, 88% (37/42) gastric and 63% (29/46) hepatocellular tumors. PRDM5 was further found a stress-responsive gene, but its response was impaired when the promoter was methylated. Ectopic PRDM5 expression significantly inhibited tumor cell clonogenicity, accompanied by the inhibition of TCF/β-catenin-dependent transcription and downregulation of CDK4, TWIST1 and MDM2 oncogenes, while knocking down of PRDM5 expression lead to increased cell proliferation. ChIP assay showed that PRDM5 bound to its target gene promoters and suppressed their transcription. An inverse correlation between the expression of PRDM5 and activated β-catenin was also observed in cell lines.CONCLUSIONS/SIGNIFICANCE:PRDM5 functions as a tumor suppressor at least partially through antagonizing aberrant WNT/β-catenin signaling and oncogene expression. Frequent epigenetic silencing of PRDM5 is involved in multiple tumorigeneses, which could serve as a tumor biomarker.

The Functions and Mechanisms of PR-DUB in Malignancy

PR-DUB maintains the expression of critical genes through FOXK1/2- and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1

Polycomb Repressor Complex: Its Function in Human Cancer and Therapeutic Target Strategy.

Unconventional structure and function of PHD domains from Additional Sex Combs-like proteins

Polycomb Genes, Mirna, and Their Deregulation in B-cell Malignancies.

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

Additional Sex Combs-like Family Associated with Epigenetic Regulation

ASXL1/2 mutations and myeloid malignancies

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

DAXX in cancer: phenomena, processes, mechanisms and regulation

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network

MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer

Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma

PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function

A Deregulated M6a Writer Complex Axis Driven by BRD4 Confers an Epitranscriptomic Vulnerability in Combined DNA Repair-Targeted Therapy.

Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Role of H2B Mono-Ubiquitination in the Initiation and Progression of Cancer

Regulation and Role of Post-Translational Modifications of Enhancer of Zeste Homologue 2 in Cancer Development.

Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction